相关临床试验
6
2 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
1
16.7%
已完成
4
66.7%
尚未招募
1
16.7%
- Procter & Gamble's Gillette closed on the 232 A Street development in South Boston for $99.29 million, taking over the entire site from Breakthrough Properties. - Gillette, which has operated in Boston for nearly 125 years, pledged to invest close to $1 billion in the project. - Breakthrough Properties originally paid $80 million for the property in 2021 and secured approval for a 325,000 square foot research and development campus. - JLL reports life science real estate demand is recovering, with Boston, San Diego, the Bay Area and Raleigh-Durham recording nearly 8 million square feet of absorption in the first quarter, up 44% year-over-year.
- A 2nd U.S. Circuit Court of Appeals panel revived portions of nationwide litigation alleging drugmakers sold billions of dollars in oral phenylephrine decongestants that were no better than placebo. - The court allowed claims over "maximum strength" labeling and brand-name drugs approved through the New Drug Application process to proceed, while preempting most state law-based claims. - An FDA advisory panel concluded in September 2023 that oral phenylephrine was ineffective as a decongestant, and the FDA proposed removing the ingredient from OTC cold medications in November 2024. - Circuit Judge Denny Chin acknowledged the apparent unfairness but stated the remedy "must flow not from litigation but from the FDA."
- The global precision biotics market was valued at USD 4.90 billion in 2025 and is projected to reach approximately USD 17.46 billion by 2035, expanding at a CAGR of 13.55%. - The probiotics segment dominated with a 34% market share in 2025, while precision microbiome therapeutics is expected to grow at the fastest CAGR of 18.6% through 2035. - North America led the market with a 39% revenue share in 2025, while Asia Pacific is forecast to grow at the strongest regional CAGR of 17.3%. - Advances in AI, next-generation sequencing, and CRISPR-based microbial engineering are accelerating strain discovery and clinical validation of targeted microbiome interventions.
- Thibaut Mongon has departed as CEO of Kenvue, the consumer health company that makes Listerine and Band-Aid brands, as the company continues its strategic review process. - Board member Kirk Perry, former CEO of Circana and 20-year Procter & Gamble veteran, has been appointed as interim CEO effective immediately. - The company's board is exploring various strategic alternatives including portfolio simplification and operational changes, with shares rising over 4% following the announcement. - Kenvue reported preliminary second-quarter earnings guidance of 28-29 cents per share, meeting analyst expectations, with full results scheduled for August 7.
